White Paper

July 24, 2020| By

How We Capture Mechanism of Action in the Notable Platform

Getting the right cancer drugs to the right patients relies on the accurate prediction of clinical response to an ever-increasing array of cancer therapies. Although genomics-based precision medicine approaches fulfill this need for some patients by revealing druggable genomic alterations, they do not always identify the optimal drug or result in a clinical response.

To address this critical unmet need, Notable has developed a custom precision medicine platform to directly test patient cancer cell responses to drugs in an ex vivo setting. Because cancer drugs work across a wide variety of mechanisms, an ex vivo drug sensitivity platform requires a high degree of versatility.